Search - tctmd.com

Displaying 1 - 20 of 34

Sort: Relevancy | Date

Presentation ACC 2025

Advance-HTN: Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension

Presenter: Luke Laffin

March 29, 2025

News Conference News ACC 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

L.A. McKeown

April 16, 2024

News Conference News ACC 2024

KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives

Shelley Wood

April 11, 2024

Presentation ACC 2024

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

Presenter: David E. Kandzari

April 08, 2024

Presentation ACC 2024

Primary Results from the Phase 2 KARDIA-2 Study

Presenter: Akshay Desai

April 07, 2024

News Conference News ACC 2024

Oral Device Noninferior to CPAP for Reducing BP in Sleep Apnea: CRESCENT

Caitlin E. Cox

April 06, 2024

Presentation ACC 2024

Mandibular Advancement versus CPAP for BP Reduction in OSA and High Cardiovascular Risk

Presenter: Ronald Chi Hang Lee

April 06, 2024

News Conference News ACC 2024

Lack of Sleep Ups Hypertension Risk, Especially for Women

Yael L. Maxwell

April 03, 2024

News Conference News ACC 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Michael O'Riordan

March 14, 2023

News Conference News ACC 2023

Keto Diet Linked to Hypercholesterolemia, Higher ASCVD Risk

Shelley Wood

March 08, 2023

News Conference News ACC 2023

HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension

Todd Neale

March 08, 2023

Presentation ACC 2023

The STELLAR Phase 3 Trial: A Study of Sotaterceptin Combination with Background Therapy for the Treatment of Pulmonary Arterial Hypertension

Presenter: Marius M. Hoeper

March 05, 2023

News Conference News ACC 2022

SPYRAL HTN-ON MED at 3 Years: Renal Denervation’s BP Impact Endures

Todd Neale

April 08, 2022

News Conference News ACC 2022

POISE-3: Two Perioperative BP Strategies Give Similar Results in Noncardiac Surgery

Todd Neale

April 06, 2022

Presentation ACC 2022

The Effects Of A Hypotension-avoidance Strategy Versus A Hypertension-avoidance Strategy In Patients Undergoing Noncardiac Surgery

Presenter: Maura Marcucci

April 04, 2022

Presentation ACC 2022

Long Term Efficacy and Safety of Renal Denervation on Blood Pressure in Patients on Antihypertension Medications: 3-Year Outcomes from the SPYRAL HTN-ON MED Trial

Presenter: Felix Mahfoud

April 04, 2022

News Conference News ACC 2022

CHAP: Better Blood Pressure Control, Better Pregnancy Outcomes

Michael O'Riordan

April 02, 2022

News Conference News ACC 2021

Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO

Michael O'Riordan

May 16, 2021

Presentation ACC 2021

Ultrasound Renal Denervation for Hypertension Resistant to a Triple Medication Pill: The Randomized Sham Controlled RADIANCE-HTN TRIO Trial

Presenter: Ajay J. Kirtane

May 16, 2021

News Conference News ACC 2021

Social Determinants of Health Tied to Fewer COVID-19 Precautions in CVD Patients

Caitlin E. Cox

May 07, 2021

Advertisement

Advance-HTN: Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

Primary Results from the Phase 2 KARDIA-2 Study

Oral Device Noninferior to CPAP for Reducing BP in Sleep Apnea: CRESCENT

Mandibular Advancement versus CPAP for BP Reduction in OSA and High Cardiovascular Risk

Lack of Sleep Ups Hypertension Risk, Especially for Women

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Keto Diet Linked to Hypercholesterolemia, Higher ASCVD Risk

HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension

The STELLAR Phase 3 Trial: A Study of Sotaterceptin Combination with Background Therapy for the Treatment of Pulmonary Arterial Hypertension

SPYRAL HTN-ON MED at 3 Years: Renal Denervation’s BP Impact Endures

POISE-3: Two Perioperative BP Strategies Give Similar Results in Noncardiac Surgery

The Effects Of A Hypotension-avoidance Strategy Versus A Hypertension-avoidance Strategy In Patients Undergoing Noncardiac Surgery

Long Term Efficacy and Safety of Renal Denervation on Blood Pressure in Patients on Antihypertension Medications: 3-Year Outcomes from the SPYRAL HTN-ON MED Trial

CHAP: Better Blood Pressure Control, Better Pregnancy Outcomes

Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO

Ultrasound Renal Denervation for Hypertension Resistant to a Triple Medication Pill: The Randomized Sham Controlled RADIANCE-HTN TRIO Trial

Social Determinants of Health Tied to Fewer COVID-19 Precautions in CVD Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content